-
2
-
-
0031012884
-
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases
-
Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.
-
(1997)
J Thorac Cardiovasc Surg.
, vol.113
, pp. 37-49
-
-
Pastorino, U.1
Buyse, M.2
Friedel, G.3
-
3
-
-
0031052731
-
Liver resection for colorectal metastases
-
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946.
-
(1997)
J Clin Oncol.
, vol.15
, pp. 938-946
-
-
Fong, Y.1
Cohen, A.M.2
Fortner, J.G.3
-
4
-
-
70249110476
-
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients
-
de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–448.
-
(2009)
Ann Surg.
, vol.250
, pp. 440-448
-
-
de Jong, M.C.1
Pulitano, C.2
Ribero, D.3
-
5
-
-
68949209656
-
Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease
-
Carpizo DR, D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol. 2009;16:2411–2421.
-
(2009)
Ann Surg Oncol.
, vol.16
, pp. 2411-2421
-
-
Carpizo, D.R.1
D'Angelica, M.2
-
6
-
-
84861581912
-
Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study
-
Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–886.
-
(2012)
Int J Radiat Oncol Biol Phys.
, vol.83
, pp. 878-886
-
-
Milano, M.T.1
Katz, A.W.2
Zhang, H.3
Okunieff, P.4
-
7
-
-
67349257418
-
Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy
-
Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–608.
-
(2009)
Breast Cancer Res Treat.
, vol.115
, pp. 601-608
-
-
Milano, M.T.1
Zhang, H.2
Metcalfe, S.K.3
Muhs, A.G.4
Okunieff, P.5
-
8
-
-
84937974394
-
Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)
-
Garcia-Cabezas S, Bueno C, Rivin E, Roldan JM, Palacios-Eito A. Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT). Clin Transl Oncol. 2016;17:668–672.
-
(2016)
Clin Transl Oncol.
, vol.17
, pp. 668-672
-
-
Garcia-Cabezas, S.1
Bueno, C.2
Rivin, E.3
Roldan, J.M.4
Palacios-Eito, A.5
-
9
-
-
84912075430
-
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
-
Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014;25:1954–1959.
-
(2014)
Ann Oncol.
, vol.25
, pp. 1954-1959
-
-
Collen, C.1
Christian, N.2
Schallier, D.3
-
10
-
-
84863716833
-
High dose stereotactic body radiotherapy using 3 fractions for colorectal oligometastases
-
Bae SH, Kim MS, Cho CK, et al. High dose stereotactic body radiotherapy using 3 fractions for colorectal oligometastases. J Surg Oncol. 2012;106:138–143.
-
(2012)
J Surg Oncol.
, vol.106
, pp. 138-143
-
-
Bae, S.H.1
Kim, M.S.2
Cho, C.K.3
-
11
-
-
63749100778
-
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases
-
Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–1584.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 1579-1584
-
-
Rusthoven, K.E.1
Kavanagh, B.D.2
Burri, S.H.3
-
12
-
-
63749100778
-
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases
-
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–1578.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 1572-1578
-
-
Rusthoven, K.E.1
Kavanagh, B.D.2
Cardenes, H.3
-
13
-
-
84926222348
-
Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases
-
Fode MM, Hoyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015;114:155–160.
-
(2015)
Radiother Oncol.
, vol.114
, pp. 155-160
-
-
Fode, M.M.1
Hoyer, M.2
-
14
-
-
84991987379
-
Surgery or ablative radiotherapy for breast cancer oligometastases
-
Salama JK, Chmura SJ. Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc Clin Oncol Educ Book. 2015;35:e8–e15.
-
(2015)
Am Soc Clin Oncol Educ Book.
, vol.35
, pp. e8-e15
-
-
Salama, J.K.1
Chmura, S.J.2
-
15
-
-
84861334635
-
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
-
Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118:2962–2970.
-
(2012)
Cancer.
, vol.118
, pp. 2962-2970
-
-
Salama, J.K.1
Hasselle, M.D.2
Chmura, S.J.3
-
16
-
-
10744228140
-
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
-
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181.
-
(2003)
Semin Radiat Oncol.
, vol.13
, pp. 176-181
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
-
17
-
-
0028969271
-
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
-
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346.
-
(1995)
Int J Radiat Oncol Biol Phys.
, vol.31
, pp. 1341-1346
-
-
Cox, J.D.1
Stetz, J.2
Pajak, T.F.3
-
18
-
-
83255163997
-
MicroRNA expression characterizes oligometastasis(es)
-
Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6:e28650.
-
(2011)
PLoS One.
, vol.6
-
-
Lussier, Y.A.1
Xing, H.R.2
Salama, J.K.3
-
20
-
-
84926507971
-
limma powers differential expression analyses for RNA-sequencing and microarray studies [serial online]
-
Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies [serial online]. Nucleic Acids Res. 2015;43:e47.
-
(2015)
Nucleic Acids Res.
, vol.43
-
-
Ritchie, M.E.1
Phipson, B.2
Wu, D.3
-
21
-
-
0001677717
-
Controlling the false discovery rate: a practical and powerful approach to multiple testing
-
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300.
-
(1995)
J R Stat Soc B.
, vol.57
, pp. 289-300
-
-
Benjamini, Y.1
Hochberg, Y.2
-
22
-
-
77950537175
-
Regularization paths for generalized linear models via coordinate descent
-
Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
-
(2010)
J Stat Softw.
, vol.33
, pp. 1-22
-
-
Friedman, J.1
Hastie, T.2
Tibshirani, R.3
-
23
-
-
77955157844
-
JM: an R package for the joint modelling of longitudinal and time-to-event data
-
Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. J Stat Soft. 2010;35:1–33.
-
(2010)
J Stat Soft.
, vol.35
, pp. 1-33
-
-
Rizopoulos, D.1
-
24
-
-
57649100364
-
Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy
-
McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:112–118.
-
(2009)
Int J Radiat Oncol Biol Phys.
, vol.73
, pp. 112-118
-
-
McCammon, R.1
Schefter, T.E.2
Gaspar, L.E.3
Zaemisch, R.4
Gravdahl, D.5
Kavanagh, B.6
-
25
-
-
84893379567
-
Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival
-
de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25:467–471.
-
(2014)
Ann Oncol.
, vol.25
, pp. 467-471
-
-
de Vin, T.1
Engels, B.2
Gevaert, T.3
Storme, G.4
De Ridder, M.5
-
26
-
-
84907011125
-
Radical irradiation of extracranial oligometastases
-
Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32:2902–2912.
-
(2014)
J Clin Oncol.
, vol.32
, pp. 2902-2912
-
-
Salama, J.K.1
Milano, M.T.2
-
27
-
-
84909581571
-
The oligometastatic state-separating truth from wishful thinking
-
Palma DA, Salama JK, Lo SS, et al. The oligometastatic state-separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11:549–557.
-
(2014)
Nat Rev Clin Oncol.
, vol.11
, pp. 549-557
-
-
Palma, D.A.1
Salama, J.K.2
Lo, S.S.3
-
28
-
-
84870945783
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs [serial online]
-
Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs [serial online]. PLoS One. 2012;7:e50141.
-
(2012)
PLoS One.
, vol.7
-
-
Lussier, Y.A.1
Khodarev, N.N.2
Regan, K.3
-
29
-
-
84924251051
-
14q32-Encoded microRNAs mediate an oligometastatic phenotype
-
Uppal A, Wightman SC, Mallon S, et al. 14q32-Encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015;6:3540–3552.
-
(2015)
Oncotarget.
, vol.6
, pp. 3540-3552
-
-
Uppal, A.1
Wightman, S.C.2
Mallon, S.3
-
30
-
-
82555193281
-
Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis [serial online]
-
Zhang H, Hao Y, Yang J, et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis [serial online]. Nat Commun. 2011;2:554.
-
(2011)
Nat Commun.
, vol.2
, pp. 554
-
-
Zhang, H.1
Hao, Y.2
Yang, J.3
-
31
-
-
84899647898
-
MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2
-
Li W, Liu Z, Chen L, Zhou L, Yao Y. MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. FEBS Lett. 2014;588:1608–1615.
-
(2014)
FEBS Lett.
, vol.588
, pp. 1608-1615
-
-
Li, W.1
Liu, Z.2
Chen, L.3
Zhou, L.4
Yao, Y.5
-
32
-
-
84871222985
-
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer
-
Majid S, Dar AA, Saini S, et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012;72:6435–6446.
-
(2012)
Cancer Res.
, vol.72
, pp. 6435-6446
-
-
Majid, S.1
Dar, A.A.2
Saini, S.3
-
33
-
-
84870021606
-
Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer [serial online]
-
Zaman MS, Thamminana S, Shahryari V, et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer [serial online]. PLoS One. 2012;7:e50203.
-
(2012)
PLoS One.
, vol.7
-
-
Zaman, M.S.1
Thamminana, S.2
Shahryari, V.3
-
34
-
-
84877766516
-
Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer
-
Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, Alahari SK. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer. Cancer Res. 2013;73:2884–2896.
-
(2013)
Cancer Res.
, vol.73
, pp. 2884-2896
-
-
Jin, L.1
Wessely, O.2
Marcusson, E.G.3
Ivan, C.4
Calin, G.A.5
Alahari, S.K.6
-
35
-
-
79952706449
-
miR-449 inhibits cell proliferation and is down-regulated in gastric cancer [serial online]
-
Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer [serial online]. Mol Cancer. 2011;10:29.
-
(2011)
Mol Cancer.
, vol.10
, pp. 29
-
-
Bou Kheir, T.1
Futoma-Kazmierczak, E.2
Jacobsen, A.3
-
36
-
-
84944879420
-
MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets [serial online]
-
Chen SP, Liu BX, Xu J, et al. MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets [serial online]. BMC Cancer. 2015;15:706.
-
(2015)
BMC Cancer.
, vol.15
, pp. 706
-
-
Chen, S.P.1
Liu, B.X.2
Xu, J.3
-
37
-
-
70350111289
-
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A
-
Yang X, Feng M, Jiang X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388–2393.
-
(2009)
Genes Dev.
, vol.23
, pp. 2388-2393
-
-
Yang, X.1
Feng, M.2
Jiang, X.3
-
38
-
-
64949190804
-
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer
-
Noonan EJ, Place RF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009;28:1714–1724.
-
(2009)
Oncogene.
, vol.28
, pp. 1714-1724
-
-
Noonan, E.J.1
Place, R.F.2
Pookot, D.3
-
39
-
-
84924408128
-
High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy
-
Mortensen MM, Hoyer S, Orntoft TF, Sorensen KD, Dyrskjot L, Borre M. High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. BMC Cancer. 2014;14:859.
-
(2014)
BMC Cancer.
, vol.14
, pp. 859
-
-
Mortensen, M.M.1
Hoyer, S.2
Orntoft, T.F.3
Sorensen, K.D.4
Dyrskjot, L.5
Borre, M.6
|